Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | CASP7 | P55210 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429528 | 0.84 | MAPT (0.47) | MAPTGAALMNAMAOAMAOB | |
| SCHEMBL8578811 | 0.81 | MAOB (0.64) | MAPTGAALMNAMAOAMAOB | |
| SCHEMBL6209577 | 0.78 | MAOB (0.51) | MAPTGAALMNAMAOAMAOB | |
| SCHEMBL5544630 | 0.78 | MAOB (0.47) | MAPTMAOAMAOBHSD17B10CASP1 | |
| SCHEMBL1924055 | 0.76 | MAOB (0.54) | MAPTMAOAMAOBHSD17B10MEN1 | |
| SCHEMBL563933 | 0.76 | MAOB (0.68) | MAPTMAOAMAOBHSD17B10MEN1 | |
| SCHEMBL2227219 | 0.76 | MAOB (0.46) | MAPTMAOAMAOBHSD17B10CASP1 | |
| SCHEMBL1429041 | 0.76 | MAOB (0.46) | MAPTLMNAMAOAMAOBHSD17B10 | |
| SCHEMBL2056164 | 0.76 | MAOB (0.54) | MAPTMAOAMAOBHSD17B10CASP1 | |
| SCHEMBL29409544 | 0.76 | MAOB (0.68) | MAPTMAOAMAOBHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751127-B1 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | INTERMED DISCOVERY GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-1751127-B1 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | INTERMED DISCOVERY GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1751127-A2 | NOVEL CYLOPENTA¬B|BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | Bayer HealthCare AG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113529-A2 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | BAYER HEALTHCARE AG (DE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | FKBP1A, FKBP2, FKBP1B | MAPT 4239/4885GAA 2604/4885LMNA 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.